5‐HT2C receptor modulation and the treatment of obesity

[1]  I. Lucki,et al.  Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. , 1989, The Journal of pharmacology and experimental therapeutics.

[2]  D. B. Vaupel,et al.  Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens , 1982, Pharmacology Biochemistry and Behavior.

[3]  R. Hen,et al.  Absence of Fenfluramine-Induced Anorexia and Reduced c-fos Induction in the Hypothalamus and Central Amygdaloid Complex of Serotonin 1B Receptor Knock-Out Mice , 1998, The Journal of Neuroscience.

[4]  G. Bray.  Obesity: a time bomb to be defused , 1998, The Lancet.

[5]  P. Cowen,et al.  5-HT2C receptor activation decreases appetite and body weight in obese subjects , 1997, Psychopharmacology.

[6]  N. Rowland,et al.  Neurobiology of an anorectic drug: Fenfluramine , 1986, Progress in Neurobiology.

[7]  R. Samanin,et al.  Role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat. , 1992, European journal of pharmacology.

[8]  B. Hoebel,et al.  Feeding increases extracellular serotonin in the lateral hypothalamus of the rat as measured by microdialysis , 1989, Brain Research.

[9]  J. Palacios,et al.  The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. , 1984, European journal of pharmacology.

[10]  J. Blundell,et al.  Evidence for the effect of tryptophan on the pattern of food consumption in free feeding and food deprived rats. , 1979, Life sciences.

[11]  K. Goa,et al.  Sibutramine. A review of its contribution to the management of obesity. , 1998, Drugs.

[12]  T. Bartness,et al.  Increased food intake, body weight, and adiposity in rats after regional neurochemical depletion of serotonin. , 1981, Journal of comparative and physiological psychology.

[13]  G. Kennett,et al.  Potencies of antagonists indicate that 5‐HT1C receptors mediate 1–3(chlorophenyl)piperazine‐induced hypophagia , 1991, British journal of pharmacology.

[14]  E. Stricker,et al.  Hyperphagia and increased growth in rats after intraventricular injection of 5,7-dihydroxytryptamine. , 1976, Science.

[15]  H. Jackson,et al.  Investigation of the mechanisms underlying the hypophagic effects of the 5‐HT and noradrenaline reuptake inhibitor, sibutramine, in the rat , 1997, British journal of pharmacology.

[16]  Shelagh Wilson,et al.  Interactions Between Leptin and Hypothalamic Neuropeptide Y Neurons in the Control of Food Intake and Energy Homeostasis in the Rat , 1997, Diabetes.

[17]  B. Erens,et al.  The Health Survey for England , 1999 .

[18]  J. Halford,et al.  Behavioral Satiety Sequence (BSS) for the Diagnosis of Drug Action on Food Intake , 1998, Pharmacology Biochemistry and Behavior.

[19]  L. Tecott,et al.  Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene , 1998, Nature Medicine.

[20]  D. Murphy,et al.  Lack of Cross-Tolerance for Hypophagia Induced by DOI versus m-CPP Suggests Separate Mediation by 5-HT2A and 5-HT2C Receptors, Respectively , 1995, Neuropsychopharmacology.

[21]  É. Mezey,et al.  Distribution of serotonin 5‐HT1C receptor mRNA in adult rat brain , 1989, FEBS letters.

[22]  P. Conn,et al.  A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G A Colditz,et al.  Current estimates of the economic cost of obesity in the United States. , 1998, Obesity research.

[24]  B. Guy-grand.  Clinical studies with d-fenfluramine. , 1992, The American journal of clinical nutrition.

[25]  T. Blackburn,et al.  BW 723C86, a 5-HT2B Receptor Agonist, Causes Hyperphagia and Reduced Grooming in Rats , 1997, Neuropharmacology.

[26]  H. Grill,et al.  Serotonin receptors in the caudal brainstem are necessary and sufficient for the anorectic effect of peripherally administered mCPP , 1998, Psychopharmacology.

[27]  J. Halford,et al.  The 5-HT2 Receptor Agonist MK-212 Reduces Food Intake and Increases Resting but Prevents the Behavioural Satiety Sequence , 1997, Pharmacology Biochemistry and Behavior.

[28]  C. Dourish,et al.  Multiple serotonin receptors: opportunities for new treatments for obesity? , 1995, Obesity research.

[29]  Y. Ikada,et al.  Macrophage Activation for Antitumour Function by Muramyl Dipeptide‐protein Conjugates , 1990, The Journal of pharmacy and pharmacology.

[30]  G. Kennett,et al.  Evidence that mCPP may have behavioural effects mediated by central 5‐HT1C receptors , 1988, British journal of pharmacology.

[31]  J. Blundell.  Is there a role for serotonin (5-hydroxytryptamine) in feeding? , 1977, International journal of obesity.

[32]  J. Clemens,et al.  Substituted piperazines as central serotonin agonists: comparative specificity of the postsynaptic actions of quipazine and m-trifluoromethylphenylpiperazine. , 1981, The Journal of pharmacology and experimental therapeutics.

[33]  M. Kaufman,et al.  The 5‐HT1C Receptor , 1990, Annals of the New York Academy of Sciences.

[34]  A. Brown,et al.  SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.

[35]  G. Kennett,et al.  Effect of chronic m‐CPP on locomotion, hypophagia, plasma corticosterone and 5‐HT2C receptor levels in the rat , 1998, British journal of pharmacology.

[36]  B. Hoebel,et al.  Serotonin release in lateral and medial hypothalamus during feeding and its anticipation , 1990, Brain Research Bulletin.

[37]  S. Garattini,et al.  (—)‐m‐Chlorophenyl‐piperazine, a central 5‐hydroxytryptamine agonist, is a metabolite of trazodone , 1981, The Journal of pharmacy and pharmacology.

[38]  D. Coscina,et al.  EFFECTS OF CENTRAL 5,7‐DIHYDROXYTRYPTAMINE ON THE MEDIAL HYPOTHALAMIC SYNDROME IN RATS * , 1978, Annals of the New York Academy of Sciences.

[39]  F. Hoffmann-La.  5-HT 2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential , 1998 .

[40]  K. Flegal,et al.  Increasing Prevalence of Overweight Among US Adults: The National Health and Nutrition Examination Surveys, 1960 to 1991 , 1994 .

[41]  R. E. Noble.  Effect of cyproheptadine on appetite and weight gain in adults. , 1969, JAMA.

[42]  P. Fletcher,et al.  A comparison of the effects of the 5-HT1 agonists TFMPP and RU 24969 on feeding following peripheral or medial hypothalamic injection , 1992, Brain Research.

[43]  C. Dourish,et al.  EVIDENCE FOR THE INVOLVEMENT OF 5-HT2B/2C RECEPTORS IN MEDIATING FENFLURAMINE-INDUCED ANOREXIA IN RATS , 1995 .

[44]  R. Huupponen,et al.  Effect of chronic treatment with TFMPP, a 5-HT1 receptor agonist, on food intake, weight gain, plasma insulin and neuropeptide mRNA expression in obese Zucker rats. , 1993, European journal of pharmacology.

[45]  P. Conn,et al.  Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. , 1987, The Journal of pharmacology and experimental therapeutics.

[46]  David Julius,et al.  Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors , 1995, Nature.

[47]  J. Blundell,et al.  Characterisation of adjustments to the structure of feeding behaviour following pharmacological treatment: Effects of amphetamine and fenfluramine and the antagonism produced by pimozide and methergoline , 1980, Pharmacology Biochemistry and Behavior.

[48]  G. Kennett,et al.  5-HT1B agonists induce anorexia at a postsynaptic site. , 1987, European journal of pharmacology.

[49]  L. Tecott,et al.  Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice , 1999, Psychopharmacology.

[50]  E. Gibson,et al.  Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. , 1997, Trends in pharmacological sciences.

[51]  W. Edwards,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[52]  J. Vessey,et al.  The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. , 1998, The New England journal of medicine.

[53]  C. Plata-salamán.  Hypothalamus and the control of feeding: fifteen decades of direct association. , 1998, Nutrition.

[54]  R. Eglen,et al.  RS-102221: A Novel High Affinity and Selective, 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.

[55]  T. Jessell,et al.  5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[56]  I. Forbes,et al.  In vivo properties of SB 200646A, a 5‐HT2C/2B receptor antagonist , 1994, British journal of pharmacology.